H
Loading...
Loading...
CDC PLACES (2023, crude) estimates 14.6% of adults in Newark have diagnosed diabetes — 2.6 points above the U.S. 12% figure. Census population 311,549. New Jersey Medicare wound biologics: Novitas Solutions (JL). Hawk Medical is a national HCT/P 361 and wound-care distributor serving licensed Newark clinics — not a walk-in office.
Written for licensed providers. Reviewed by Joe Bradley, Founder & CEO. Content version 2026-09-18. Hawk Medical ships nationwide — this is not a Newark storefront.
Growth Factor Therapy for Tissue Repair in Newark, NJ for clinics & physicians. Growth factor therapy prod… Compliance support & pricing — contact Hawk Medical.
Adult arthritis here is 19.9% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. CDC PLACES (2023, crude) estimates 14.6% of adults in Newark have diagnosed diabetes — 2.6 points above the U.S. 12% figure. Together those PLACES numbers are why a city of 250k–500k still needs separate PRP and CTP protocols. growth factor therapy inventory is national; utilization is JL-local.
National Growth Factor Therapy for Tissue Repair notes (how the product actually works)JL reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Newark is 14.6% or not. PLACES is planning data. The LCD is the claim.
If you already buy growth factor therapy elsewhere, use this page as a check: homologous-use language, current Novitas Solutions article IDs, and PLACES 14.6% diabetes as the epidemiologic floor. If that is how you already practice, the catalog will fit.
CDC PLACES (2023, crude prevalence) estimates 14.6% of adults — 2.6 points above the U.S. 12% figure. Obesity is 35.9%; arthritis is 19.9%. That is place-level BRFSS modeling, not a clinic census and not a Newark trial.
Often yes, which is the point of vendor consolidation. Keep DME delivery tickets and HCT/P lot files separate so a New Jersey audit trail stays clean.
The 96.5% figure is a product-level clinical experience statistic published on our wound-care materials — not a city-specific trial. Your outcomes will depend on patient selection, offloading, and follow-up.
No. PRP (autologous) and cellular/tissue products (allograft/skin substitutes) sit on different coding and coverage paths. Novitas Solutions LCDs for CTPs do not automatically cover PRP injections. Build separate protocols and fee tickets.
If you operate in New Jersey and another MAC state, say it on the first call. JL will not port 1:1. We would rather split utilization than watch a sister clinic copy Newark tickets into the wrong jurisdiction.
Contact us to learn how Hawk Medical supports practices in Newark, NJ.
Hawk Medical is a national distributor. Joe Bradley’s clinic uses the same product classes. What is local for Newark is JL geography and published epidemiology — not a street address.
CDC PLACES 2023 crude rate for Newark — 2.6 points above the U.S. 12% figure. Planning input, not an outcomes claim.
New Jersey Part B wound biologics follow this contractor (siblings: DC, DE, MD, PA). We train to the articles. We do not write coverage.
PLACES crude adult arthritis in Newark. Useful for joint-program math; still needs a diagnosis and privileging.
No Newark storefront. Joe Bradley is an active practice owner. growth factor therapy stays in its regulatory lane — not “FDA-approved stem cell therapy.”
Experience the difference of working with a distributor who understands your practice because we operate one ourselves.